Log in to save to my catalogue

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escal...

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escal...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2501458773

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

About this item

Full title

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Publisher

London: Future Medicine Ltd

Journal title

Immunotherapy, 2021-02, Vol.13 (2), p.125-141

Language

English

Formats

Publication information

Publisher

London: Future Medicine Ltd

More information

Scope and Contents

Contents

Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE®) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies;...

Alternative Titles

Full title

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2501458773

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2501458773

Other Identifiers

ISSN

1750-743X

E-ISSN

1750-7448

DOI

10.2217/imt-2020-0256

How to access this item